Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Orion Pharma's pretax income for the
three
months ended in Mar. 2026 was BDT-135 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-694 Mil.
Orion Pharma's pretax margin was -9.08%.
During the past 12 years, Orion Pharma's highest Pretax Margin was 11.81%. The lowest was -18.46%. And the median was 10.23%.
During the past 12 years, Orion Pharma's highest Pretax Margin was 11.81%. The lowest was -18.46%. And the median was 10.23%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma Pre-Tax Income Related Terms
Orion Pharma Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Pre-Tax Income Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Pre-Tax Income vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-694 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Pre-Tax Income of BDT-694 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Pre-Tax Income too high?
Orion Pharma's current Pre-Tax Income is BDT-694 Mil. Overall, Orion Pharma has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Pre-Tax Income compare to CEG and VST?
Orion Pharma's Pre-Tax Income of BDT-694 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for an Utilities - Independent Power Producers company?
A good Pre-Tax Income depends on the Utilities - Independent Power Producers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Orion Pharma and its competitors. Orion Pharma's current Pre-Tax Income is BDT-694 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.51, compared to a current price of BDT25.00 — trading 28.1% above its estimated fair value. The current Pre-Tax Income is BDT-694 Mil. Orion Pharma's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Pre-Tax Income is BDT-694 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT25.00 is trading 28.1% above its estimated GF Value™ of BDT19.51.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Pre-Tax Income: BDT-694 Mil
GF Value™: BDT19.51 vs. price of BDT25.00 (28.1% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
75GF Score
Get the complete analysis for DHA:ORIONPHARM
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
